BPC-157:
A Research
Overview
BPC-157 is a synthetic peptide of fifteen amino acids, based on a partial sequence of a protein identified in human gastric juice. It appears extensively in preclinical laboratory literature concerned with cytoprotection and angiogenesis. It is not a licensed medicinal product and is supplied strictly for research use only.
What BPC-157 is
BPC-157 is a synthetic peptide composed of fifteen amino acids, with the sequence GEPPPGKPADDAGLV. The initials stand for Body Protection Compound, and the number refers to its position in the research literature rather than any property of the molecule. It is derived from — though not identical to — a partial sequence of a protein found naturally in human gastric juice.
It is supplied as a lyophilised (freeze-dried) white powder, the standard form for a research peptide because it is far more stable dry than in solution. See our guide to why research peptides are lyophilised for the reasoning behind that.
Background and discovery
BPC-157 emerged from research beginning in the 1990s into peptides present in the digestive tract and their apparent stability in the harsh environment of gastric juice. That unusual stability — most peptides degrade quickly in acidic, enzyme-rich conditions — is part of what drew research interest to the sequence.
Since then it has become one of the more frequently studied peptides in preclinical laboratory work. It is important to be precise about the nature of that work: the overwhelming majority of it is in-vitro (cell culture) or in animal models. BPC-157 holds no marketing authorisation in any jurisdiction and has not been evaluated for safety or efficacy in humans.
Areas of research interest
The scientific literature involving BPC-157 clusters around a few themes. In each case what is being described is the focus of laboratory research, not an established effect in people:
- Cytoprotection — the study of how cells resist and recover from injury, the research theme the compound's name refers to.
- Angiogenesis — the formation of new blood vessels, examined in cell and tissue models.
- Connective tissue models — laboratory studies involving tendon, ligament and muscle tissue.
- Gastrointestinal models — reflecting the compound's origin in gastric research.
- The nitric oxide system — a signalling pathway frequently referenced in the mechanistic literature.
These describe where the compound appears in research, not conclusions about what it does in a human being. No such conclusions are supported, and none are offered here.
Research context
BPC-157 is often examined in the same body of literature as TB-500 (a synthetic fragment related to thymosin beta-4), and the two are sometimes studied together — the subject of our BPC-157 vs TB-500 comparison; both appear in our GLOW combined research preparation. Anyone working with the compound should understand what an accompanying certificate of analysis does and does not establish about the material.
Frequently Asked Questions
BPC-157 is a synthetic peptide of fifteen amino acids (sequence GEPPPGKPADDAGLV), based on a partial sequence of a protein found in human gastric juice. The name stands for Body Protection Compound. It is supplied as a lyophilised powder for laboratory research use only.
No. BPC-157 holds no marketing authorisation in any jurisdiction and has not been evaluated for safety or efficacy in humans. The great majority of published research involving it is in-vitro or in animal models. It is supplied strictly as a reference material for laboratory research.
Preclinical research involving BPC-157 clusters around cytoprotection, angiogenesis, connective tissue models, gastrointestinal models and the nitric oxide signalling system. These describe areas of laboratory research activity, not established effects in humans.